Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Fasinumab in Osteoarthritis Pain of the Knee or Hip
2015-003783-36Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in knee osteoarthritis (OA), hip osteoarthritis and osteoarthritis (OA) comparing Fasinumab multi-dose with Placebo (2 arms). Primary endpoints: Primary safety endpoint and Use of paracetamol/acetaminophen. Started Mar 2016; status: completed.
02
Drugs
fasinumab
03
Conditions
knee osteoarthritis (OA)hip osteoarthritisosteoarthritis (OA)
Beyond the preview
Go deeper on 2015-003783-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003783-36.